214 related articles for article (PubMed ID: 30450575)
41. Allergic reactions and antiasparaginase antibodies in children with high-risk acute lymphoblastic leukemia: A children's oncology group report.
Ko RH; Jones TL; Radvinsky D; Robison N; Gaynon PS; Panosyan EH; Avramis IA; Avramis VI; Rubin J; Ettinger LJ; Seibel NL; Dhall G
Cancer; 2015 Dec; 121(23):4205-11. PubMed ID: 26308766
[TBL] [Abstract][Full Text] [Related]
42. Experience with generic pegylated L-asparaginase in children with acute lymphoblastic leukemia and monitoring of serum asparaginase activity.
Vyas C; Jain S; Kapoor G; Mehta A; Takkar Chugh P
Pediatr Hematol Oncol; 2018; 35(5-6):331-340. PubMed ID: 30488741
[TBL] [Abstract][Full Text] [Related]
43. Prospective, real-time monitoring of pegylated Escherichia coli and Erwinia asparaginase therapy in childhood acute lymphoblastic leukaemia and non-Hodgkin lymphoma in Belgium.
Mondelaers V; Ferster A; Uyttebroeck A; Brichard B; van der Werff Ten Bosch J; Norga K; Francotte N; Piette C; Vandemeulebroecke K; Verbeke C; Schmidt S; Benoit Y; Lammens T; De Moerloose B
Br J Haematol; 2020 Jul; 190(1):105-114. PubMed ID: 32057100
[TBL] [Abstract][Full Text] [Related]
44. Lack of benefit from premedication for pegylated asparaginase during pediatric acute lymphoblastic leukemia/lymphoma therapy: A side-by-side comparison.
Menig S; Dinh A; Angus J; Tucker S; Leger KJ; Rushing T; Orgel E
Pediatr Blood Cancer; 2024 Jan; 71(1):e30716. PubMed ID: 37856184
[TBL] [Abstract][Full Text] [Related]
45. Pharmacokinetics of native Escherichia coli asparaginase (Asparaginase medac) and hypersensitivity reactions in ALL-BFM 95 reinduction treatment.
Müller HJ; Beier R; Löning L; Blütters-Sawatzki R; Dörffel W; Maass E; Müller-Weihrich S; Scheel-Walter HG; Scherer F; Stahnke K; Schrappe M; Horn A; Lümkemann K; Boos J
Br J Haematol; 2001 Sep; 114(4):794-9. PubMed ID: 11564065
[TBL] [Abstract][Full Text] [Related]
46. [Efficacy observation of polyethylene glycol conjugated asparaginase for induction treatment of children with newly diagnosed acute lymphoblastic leukemia].
Liu F; Wan Y; Chang L; Guo Y; Yang W; Wang S; Chen X; Liu T; Ruan M; Zhang L; Liu X; Zou Y; Chen Y; Zhu X
Zhonghua Er Ke Za Zhi; 2014 Mar; 52(3):215-7. PubMed ID: 24824393
[TBL] [Abstract][Full Text] [Related]
47. Peg-asparaginase for acute lymphoblastic leukemia.
Rytting M
Expert Opin Biol Ther; 2010 May; 10(5):833-9. PubMed ID: 20345338
[TBL] [Abstract][Full Text] [Related]
48. Asparaginase encapsulated in erythrocytes as second-line treatment in hypersensitive patients with acute lymphoblastic leukaemia.
Lynggaard LS; Vaitkeviciene G; Langenskiöld C; Lehmann AK; Lähteenmäki PM; Lepik K; El Hariry I; Schmiegelow K; Albertsen BK
Br J Haematol; 2022 Jun; 197(6):745-754. PubMed ID: 35344210
[TBL] [Abstract][Full Text] [Related]
49. DNA-thioguanine nucleotide concentration and relapse-free survival during maintenance therapy of childhood acute lymphoblastic leukaemia (NOPHO ALL2008): a prospective substudy of a phase 3 trial.
Nielsen SN; Grell K; Nersting J; Abrahamsson J; Lund B; Kanerva J; Jónsson ÓG; Vaitkeviciene G; Pruunsild K; Hjalgrim LL; Schmiegelow K
Lancet Oncol; 2017 Apr; 18(4):515-524. PubMed ID: 28258828
[TBL] [Abstract][Full Text] [Related]
50. Parents' and Adolescents' Preferences for Intensified or Reduced Treatment in Randomized Lymphoblastic Leukemia Trials.
Tulstrup M; Larsen HB; Castor A; Rossel P; Grell K; Heyman M; Abrahamsson J; Söderhäll S; Åsberg A; Jonsson OG; Vettenranta K; Frandsen TL; Albertsen BK; Schmiegelow K;
Pediatr Blood Cancer; 2016 May; 63(5):865-71. PubMed ID: 26717887
[TBL] [Abstract][Full Text] [Related]
51. Anti-asparaginase antibodies following E. coli asparaginase therapy in pediatric acute lymphoblastic leukemia.
Woo MH; Hak LJ; Storm MC; Evans WE; Sandlund JT; Rivera GK; Wang B; Pui CH; Relling MV
Leukemia; 1998 Oct; 12(10):1527-33. PubMed ID: 9766495
[TBL] [Abstract][Full Text] [Related]
52. Cerebral sinus venous thromboses in children with acute lymphoblastic leukaemia - a multicentre study from the Nordic Society of Paediatric Haematology and Oncology.
Ranta S; Tuckuviene R; Mäkipernaa A; Albertsen BK; Frisk T; Tedgård U; Jónsson ÓG; Pruunsild K; Gretenkort Andersson N; Winther Gunnes M; Saulyte Trakymiene S; Frandsen T; Heyman M; Ruud E; Helgestad J
Br J Haematol; 2015 Feb; 168(4):547-52. PubMed ID: 25288392
[TBL] [Abstract][Full Text] [Related]
53. Toxicity profile and treatment delays in NOPHO ALL2008-comparing adults and children with Philadelphia chromosome-negative acute lymphoblastic leukemia.
Toft N; Birgens H; Abrahamsson J; Griškevičius L; Hallböök H; Heyman M; Klausen TW; Jónsson ÓG; Palk K; Pruunsild K; Quist-Paulsen P; Vaitkeviciene G; Vettenranta K; Asberg A; Helt LR; Frandsen T; Schmiegelow K
Eur J Haematol; 2016 Feb; 96(2):160-9. PubMed ID: 25867866
[TBL] [Abstract][Full Text] [Related]
54. Combination therapy with methotrexate, vincristine, polyethylene-glycol conjugated-asparaginase, and prednisone in the treatment of patients with refractory or recurrent acute lymphoblastic leukemia.
Aguayo A; Cortes J; Thomas D; Pierce S; Keating M; Kantarjian H
Cancer; 1999 Oct; 86(7):1203-9. PubMed ID: 10506705
[TBL] [Abstract][Full Text] [Related]
55. Alternative algorithm for L-asparaginase allergy in children with acute lymphoblastic leukemia.
Soyer OU; Aytac S; Tuncer A; Cetin M; Yetgin S; Sekerel BE
J Allergy Clin Immunol; 2009 Apr; 123(4):895-9. PubMed ID: 19081614
[TBL] [Abstract][Full Text] [Related]
56. Comparison of hypersensitivity reactions to PEG-asparaginase in children after intravenous and intramuscular administration.
August KJ; Miller WP; Dalton A; Shinnick S
J Pediatr Hematol Oncol; 2013 Oct; 35(7):e283-6. PubMed ID: 23619117
[TBL] [Abstract][Full Text] [Related]
57. From the Children's Oncology Group: Evidence-Based Recommendations for PEG-Asparaginase Nurse Monitoring, Hypersensitivity Reaction Management, and Patient/Family Education.
Woods D; Winchester K; Towerman A; Gettinger K; Carey C; Timmermann K; Langley R; Browne E
J Pediatr Oncol Nurs; 2017; 34(6):387-396. PubMed ID: 28602129
[TBL] [Abstract][Full Text] [Related]
58. Continuous PEGasparaginase Dosing Reduces Hypersensitivity Reactions in Pediatric ALL: A Dutch Childhood Oncology Group ALL11 Randomized Trial.
van der Sluis IM; Brigitha LJ; Fiocco M; de Groot-Kruseman HA; Bierings M; van den Bos C; de Haas V; Hoogerbrugge PM; Tissing WJE; Veening MA; Pieters R
J Clin Oncol; 2024 May; 42(14):1676-1686. PubMed ID: 38306592
[TBL] [Abstract][Full Text] [Related]
59. Thrombotic effects of asparaginase in two acute lymphoblastic leukemia protocols (NOPHO ALL-1992 versus NOPHO ALL-2000): a single-institution study.
Ruud E; Holmstrøm H; de Lange C; Natvig S; Albertsen BK; Wesenberg F
Pediatr Hematol Oncol; 2006; 23(3):207-16. PubMed ID: 16517537
[TBL] [Abstract][Full Text] [Related]
60. Comparison of allergic reactions to intravenous and intramuscular pegaspargase in children with acute lymphoblastic leukemia.
Petersen WC; Clark D; Senn SL; Cash WT; Gillespie SE; McCracken CE; Keller FG; Lew G
Pediatr Hematol Oncol; 2014 May; 31(4):311-7. PubMed ID: 24498943
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]